Harbin Medical University Cancer Hospital, Harbin Medical University, Harbin, Heilongjiang 150081, China.
Harbin Medical University Cancer Hospital, Harbin Medical University, Harbin, Heilongjiang 150081, China.
Int Immunopharmacol. 2023 Oct;123:110704. doi: 10.1016/j.intimp.2023.110704. Epub 2023 Jul 26.
Immune checkpoint inhibitors (ICIs) have shown promise in hepatocellular carcinoma (HCC) treatment. With the increasing use of ICIs in cancer treatment, identifying biomarkers that can predict the prognosis of patients receiving ICIs is of great importance. We aimed to investigate the potential of circulating immunoglobulins and the combination of Geriatric Nutritional Risk Index (GNRI) with IgM to predict prognosis in patients with HCC who received ICIs.
Clinical and pathological data were collected from 101 patients with HCC who were administered ICIs and underwent circulating immunoglobulin testing between January 2018 and December 2021. Survival analysis, Cox regression analysis, and nomogram construction were performed to evaluate the prognostic value of the indicators.
In the preliminary survival analysis, we observed a significant correlation between patient prognosis and IgM levels. Patients with low IgM had shorter survival times. Upon combining the GNRI with IgM, patients with low GNRI and IgM levels had shorter progression-free survival (PFS) and overall survival (OS) (P < 0.001). Additionally, GNRI-IgM had the highest area under the curve (AUC) and was identified as an independent prognostic marker in this study. The C-indices of the nomograms for PFS and OS were 0.797 (0.734-0.860) and 0.827 (0.778-0.876), respectively.
IgM was significantly associated with the prognosis of patients with HCC receiving ICIs. The combination of the GNRI with IgM provided superior prognostic value and served as an independent prognostic marker. The GNRI-IgM can be used to effectively identify patients with HCC who are responsive to ICIs.
免疫检查点抑制剂（ICIs）在肝细胞癌（HCC）治疗中显示出前景。随着 ICI 在癌症治疗中的应用越来越广泛，确定能够预测接受 ICI 治疗的患者预后的生物标志物非常重要。我们旨在研究循环免疫球蛋白和老年营养风险指数（GNRI）与 IgM 联合预测接受 ICI 治疗的 HCC 患者预后的潜力。
收集了 2018 年 1 月至 2021 年 12 月期间接受 ICI 治疗并进行循环免疫球蛋白检测的 101 例 HCC 患者的临床和病理数据。进行生存分析、Cox 回归分析和列线图构建，以评估指标的预后价值。
初步生存分析显示，患者预后与 IgM 水平显著相关。IgM 水平低的患者生存时间较短。将 GNRI 与 IgM 结合后，GNRI 和 IgM 水平低的患者无进展生存期（PFS）和总生存期（OS）更短（P<0.001）。此外，GNRI-IgM 在本研究中具有最高的曲线下面积（AUC），并被确定为独立的预后标志物。PFS 和 OS 列线图的 C 指数分别为 0.797（0.734-0.860）和 0.827（0.778-0.876）。
IgM 与接受 ICI 治疗的 HCC 患者的预后显著相关。GNRI 与 IgM 联合提供了更好的预后价值，并作为独立的预后标志物。GNRI-IgM 可有效识别对 ICI 有反应的 HCC 患者。
